---
title: "What are long-acting injectables?"
id: "2131"
type: "post"
slug: "what-are-long-acting-injectables"
published_at: "2026-11-17T07:58:21+00:00"
modified_at: "2026-11-17T08:10:43+00:00"
url: "https://innocorepharma.com/news-events/what-are-long-acting-injectables/"
markdown_url: "https://innocorepharma.com/news-events/what-are-long-acting-injectables.md"
taxonomy_category:
  - "Science Publications"
---

17 November 2026 | Science Publications

# What are long-acting injectables?

Long-acting injectables (LAIs) are dosage forms designed to release an active pharmaceutical ingredient (API) over an extended period following administration. Instead of making the full dose available immediately, a long-acting formulation controls how the API becomes available over time. The intended release period is defined by the target product profile and may range from days to several months, depending on the product.

Achieving this behavior requires more than slowing drug release. The delivery system must accommodate the molecule, maintain appropriate quality attributes and provide a reproducible release profile. For peptides and biologics in particular, the relationship between API properties, formulation design and polymer behavior is central to development.

## How do long-acting injectables work?

In [long-acting injectable development](https://innocorepharma.com/long-acting-injectable-development/)
, the API is incorporated into a delivery system designed to regulate its release after administration. In polymer-based systems, the API may be dispersed or encapsulated within a matrix whose composition and physical properties influence how water enters the formulation and how the drug is released.

Several mechanisms may contribute to sustained release:

### Diffusion

The API moves through the hydrated delivery matrix into the surrounding environment.

### Swelling

Water uptake changes the structure and transport properties of the polymer matrix, potentially affecting the movement of the API.

### Polymer degradation

Chemical breakdown of a biodegradable matrix can alter its structure and contribute to API release.

### Matrix erosion

Gradual loss of matrix material may contribute to release, depending on the formulation.

These mechanisms are not necessarily independent. A polymer matrix may absorb water, swell and degrade while the API diffuses through it. Their relative contribution depends on the formulation and can change during the release period.

The resulting **release profile of a long-acting injectable** is therefore influenced by both the properties of the API and the design of the delivery system. A target release duration alone does not establish whether a formulation can achieve that duration reproducibly.

## What makes a formulation long-acting?

A long-acting formulation is defined by its intended extended release behavior, not simply by the presence of a particular polymer or dosage form. The delivery system must regulate the availability of the API over a period that is relevant to the target product profile.

Two formulations containing the same API may behave differently when their polymer composition, drug loading, physical structure or manufacturing process changes. Even when both are designed for sustained release, they may differ in initial release, the rate of subsequent release and the duration over which the API remains available.

This distinction matters because the intended release period and the experimentally observed release profile are not the same thing. The first is a development objective; the second must be established through appropriate formulation studies and [analytical testing](https://innocorepharma.com/analytical-development/)
.

## Which types of long-acting injectables are available?

Long-acting drug delivery can be achieved through several dosage forms. They differ in how the formulation is prepared, administered and transformed after administration. Each approach also introduces different requirements for [formulation development](https://innocorepharma.com/pharmaceutical-formulation-development/)
 and manufacturing.

| Dosage form | How it works | Important development considerations |
| --- | --- | --- |
| Microspheres | The API is incorporated into small polymer particles that provide a sustained-release matrix. | Particle size distribution, drug loading, initial release, injectability and process reproducibility. |
| In situ forming depots | An administered formulation forms a depot at the injection site, from which the API is subsequently released. | Depot formation, formulation viscosity, solvent or phase-transition behavior and release reproducibility. |
| Injectable gels | A gel-based system retains the API and regulates its release through transport within, and potentially changes to, the gel matrix. | Gel structure, viscosity, swelling, API stability and release behavior. |
| Implants | A solid delivery system provides sustained release after placement at the intended administration site. | Implant dimensions, placement method, drug distribution, matrix properties and degradation behavior where applicable. |

These dosage forms should not be treated as interchangeable. A microsphere suspension has different administration and manufacturing requirements from an implant or an in situ forming depot. The appropriate approach depends on the API, required dose, intended release profile and route of administration.

## Why are long-acting injectables developed?

Long-acting injectables are considered when the target product profile calls for sustained API release rather than immediate availability following administration. This may be relevant when a development program aims to establish a longer interval between administrations or create a dosage form with a particular release profile.

For a pharmaceutical development team, the objective is not simply to maximize release duration. A formulation designed to release an API over several months is only useful as a development candidate if its release behavior, stability, drug loading and manufacturability can be evaluated against the intended product requirements.

Consequently, the value of a long-acting approach must be assessed for the individual molecule. A technically achievable release duration does not, by itself, demonstrate clinical benefit or suitability for a particular therapeutic application.

## Why do peptides and biologics require particular attention?

Peptides and biologics can introduce formulation considerations that differ from those associated with many small-molecule APIs. Molecular structure, solubility, conformational stability and sensitivity to processing conditions may influence the suitability of a delivery system.

For proteins and other structurally complex molecules, development may need to establish whether the API retains the required molecular integrity during formulation, storage and release. Processing conditions and the microenvironment within the delivery matrix can also affect stability, depending on the specific API and polymer system.

These considerations make polymer selection particularly important. A polymer is not simply an inactive container for the API: its composition, water uptake, physical structure and degradation characteristics can influence both the formulation environment and the release profile.

## How does SynBiosys® support polymer-based drug delivery?

Innocore’s proprietary SynBiosys® platform uses biodegradable multi-block copolymers containing hydrophilic and hydrophobic domains. The hydrophilic, PEG-containing domains absorb water and swell, while the hydrophobic crystalline domains provide physical cross-links that contribute to the structure of the polymer matrix.

This combination allows polymer composition and matrix properties to be considered together when developing formulations for peptides and biologics. Water uptake, swelling, diffusion and polymer hydrolysis are relevant to the way an incorporated API may be released over time.

The suitability of SynBiosys® for a particular molecule must still be established experimentally. API stability, required drug loading, target release duration and the intended dosage form all influence the formulation strategy. Platform characteristics provide development options, but they do not eliminate the need for molecule-specific feasibility studies.

## What determines whether a long-acting injectable can be developed?

Not every API can be incorporated into every long-acting delivery system. Before a formulation approach is selected, the development team needs to understand the molecule and the requirements of the intended product.

Relevant considerations include molecular size and structure, solubility, stability, required dose, target release duration and the intended route of administration. The availability of API material and the analytical methods needed to evaluate early formulations can also affect the feasibility assessment.

These factors are connected. A formulation may demonstrate sustained release but fail to accommodate the required dose, or it may achieve an encouraging laboratory release profile while introducing processing or stability limitations.

Assessing the **feasibility of a long-acting injectable formulation** therefore involves determining which requirements can be met together, rather than evaluating release duration in isolation.

## Frequently asked questions about long-acting injectables

 What is the difference between a long-acting injectable and an immediate-release injection? An immediate-release injection is generally designed to make the API available relatively quickly after administration. A long-acting injectable uses a formulation or delivery system intended to regulate API release over an extended period. The distinction concerns drug release behavior, not necessarily the injection route.

  How long can a long-acting injectable release an API? Release duration varies by molecule, formulation and delivery technology. Some long-acting products are designed for release over days or weeks, while others target several months. The achievable duration and release profile must be established for each formulation.

  Are all long-acting injectables based on biodegradable polymers? No. Long-acting drug delivery can use different formulation principles, including biodegradable and non-biodegradable systems. Polymer-based microspheres, depots, gels and implants are important approaches, but the properties and release mechanisms vary between technologies.

  Can peptides and biologics be formulated as long-acting injectables? Peptides and biologics can be investigated for long-acting injectable development. Feasibility depends on the molecule’s stability, dose requirements, compatibility with the selected formulation conditions and the ability to achieve an appropriate release profile.

  Does a longer release period automatically mean a better formulation? No. The release period must match the target product profile. A longer duration is not inherently preferable if the formulation cannot achieve the required drug loading, molecular stability, release reproducibility or other critical quality attributes.

## Discuss your long-acting injectable development program

Innocore supports pharmaceutical and biotechnology companies developing long-acting injectable dosage forms, with particular expertise in peptides and biologics. Its formulation, polymer and analytical development capabilities help teams evaluate molecule-specific requirements and investigate suitable sustained-release approaches.

Contact Innocore to discuss the technical feasibility of a long-acting formulation for your API.

[Contact Innocore](https://innocorepharma.com/contact-us/)

Related insights

[26 July 2018 | Funding InnoCore and Merck enter global collaboration Merck and InnoCore Pharmaceuticals to Improve Patient Compliance with New Drug Delivery Technology. Read the full story](https://innocorepharma.com/news-events/innocore-and-merck-enter-global-collaboration/)
[11 September 2020 | Funding Bill & Melinda Gates Foundation Grant Awarded InnoCore Pharmaceuticals has been awarded a grant by the Bill & Melinda Gates Foundation to develop a long-acting injectable contraceptive implant. Read the full story](https://innocorepharma.com/news-events/innocore-awarded-grant-by-the-bill-melinda-gates-foundation-in-contraception/)
[01 January 2021 | Funding InnoCore leads Consortium in Influenza vaccines InnoCore Pharmaceuticals has secured funding from the European Regional Development Fund to develop a biodegradable polymer-based microneedle array patch. Read the full story](https://innocorepharma.com/news-events/innocore-leads-consortium-in-influenza-vaccines/)
